A systematic review of the health economic consequences of quadrivalent influenza vaccination

de Boer PT, van Maanen BM, Damm O, Ultsch B, Dolk FCK, Crepey P, Pitman R, Wilschut JC, Postma MJ (2017)
Expert Review of Pharmacoeconomics & Outcomes Research 17(3): 249-265.

Download
No fulltext has been uploaded. References only!
Journal Article | Review | Published | English

No fulltext has been uploaded

Author
; ; ; ; ; ; ; ;
Abstract
Background: Quadrivalent influenza vaccines (QIVs) contain antigens derived from an additional influenza type B virus as compared with currently used trivalent influenza vaccines (TIVs). This should overcome a potential reduced vaccine protection due to mismatches between TIV and circulating B viruses. In this study, we systematically reviewed the available literature on health economic evaluations of switching from TIV to QIV.Areas covered: The databases of Medline and Embase were searched systematically to identify health economic evaluations of QIV versus TIV published before September 2016.A total of sixteen studies were included, thirteen cost-effectiveness analyses and three cost-comparisons.Expert commentary: Published evidence on the cost-effectiveness of QIV suggests that switching from TIV to QIV would be a valuable intervention from both the public health and economic viewpoint. However, more research seems mandatory. Our main recommendations for future research include: 1) more extensive use of dynamic models in order to estimate the full impact of QIV on influenza transmission including indirect effects, 2) improved availability of data on disease outcomes and costs related to influenza type B viruses, and 3) more research on immunogenicity of natural influenza infection and vaccination, with emphasis on cross-reactivity between different influenza B viruses and duration of protection.
Publishing Year
ISSN
eISSN
PUB-ID

Cite this

de Boer PT, van Maanen BM, Damm O, et al. A systematic review of the health economic consequences of quadrivalent influenza vaccination. Expert Review of Pharmacoeconomics & Outcomes Research. 2017;17(3):249-265.
de Boer, P. T., van Maanen, B. M., Damm, O., Ultsch, B., Dolk, F. C. K., Crepey, P., Pitman, R., et al. (2017). A systematic review of the health economic consequences of quadrivalent influenza vaccination. Expert Review of Pharmacoeconomics & Outcomes Research, 17(3), 249-265. doi:10.1080/14737167.2017.1343145
de Boer, P. T., van Maanen, B. M., Damm, O., Ultsch, B., Dolk, F. C. K., Crepey, P., Pitman, R., Wilschut, J. C., and Postma, M. J. (2017). A systematic review of the health economic consequences of quadrivalent influenza vaccination. Expert Review of Pharmacoeconomics & Outcomes Research 17, 249-265.
de Boer, P.T., et al., 2017. A systematic review of the health economic consequences of quadrivalent influenza vaccination. Expert Review of Pharmacoeconomics & Outcomes Research, 17(3), p 249-265.
P.T. de Boer, et al., “A systematic review of the health economic consequences of quadrivalent influenza vaccination”, Expert Review of Pharmacoeconomics & Outcomes Research, vol. 17, 2017, pp. 249-265.
de Boer, P.T., van Maanen, B.M., Damm, O., Ultsch, B., Dolk, F.C.K., Crepey, P., Pitman, R., Wilschut, J.C., Postma, M.J.: A systematic review of the health economic consequences of quadrivalent influenza vaccination. Expert Review of Pharmacoeconomics & Outcomes Research. 17, 249-265 (2017).
de Boer, Pieter T., van Maanen, Britt M., Damm, Oliver, Ultsch, Bernhard, Dolk, Franklin C. K., Crepey, Pascal, Pitman, Richard, Wilschut, Jan C., and Postma, Maarten J. “A systematic review of the health economic consequences of quadrivalent influenza vaccination”. Expert Review of Pharmacoeconomics & Outcomes Research 17.3 (2017): 249-265.
This data publication is cited in the following publications:
This publication cites the following data publications:

2 Citations in Europe PMC

Data provided by Europe PubMed Central.

The cost-effectiveness of trivalent and quadrivalent influenza vaccination in communities in South Africa, Vietnam and Australia.
de Boer PT, Kelso JK, Halder N, Nguyen TP, Moyes J, Cohen C, Barr IG, Postma MJ, Milne GJ., Vaccine 36(7), 2018
PMID: 29373192
Cost-effectiveness analysis of quadrivalent seasonal influenza vaccines in England.
Thorrington D, van Leeuwen E, Ramsay M, Pebody R, Baguelin M., BMC Med 15(1), 2017
PMID: 28882149

Export

0 Marked Publications

Open Data PUB

Web of Science

View record in Web of Science®

Sources

PMID: 28613092
PubMed | Europe PMC

Search this title in

Google Scholar